ネオ抗原がんワクチンの世界市場 2020年：企業別、地域別、種類・用途別

• 英文タイトル：Global Neoantigen Cancer Vaccine Market 2020 by Company, Regions, Type and Application, Forecast to 2025

• レポートコード：D0804-16145 • 出版社/出版日：GlobalInfoResearch / 2020年7月28日 ※2025年版があります。お問い合わせください。 • レポート形態：英語、PDF、103ページ • 納品方法：Eメール • 産業分類：医療

• 販売価格（消費税別）

Single User	￥504,600 (USD3,480)	▷ お問い合わせ
Multi User	￥756,900 (USD5,220)	▷ お問い合わせ
Corporate User	￥1,009,200 (USD6,960)	▷ お問い合わせ

• ご注文方法：お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法：銀行振込（納品後、ご請求書送付）

---

レポート概要

---

本調査レポートでは、ネオ抗原がんワクチンの世界市場を広く調査・分析し、今後の市場展望をまとめております。ネオ抗原がんワクチンの種類別市場規模（個別化ワクチン、市販ネオワクチン）、用途別市場規模（病院、クリニック、その他）、地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、中国、日本、東南アジア、南米、中東、アフリカなど）、市場動向、企業別販売量と市場シェアなどの情報を掲載しています。 ・市場概要 ・企業情報（販売量、市場シェア、製品概要、SWOT分析）：Roche、Neon Therapeutics、Advaxis、Medimmune、Gritstone Oncology、Merck、OSE Immunotherapeutics、Genocea、Agenus、Nouscom、Medigene、Geneos Therapeutics、Vaccibody、Brightpath Biotherapeutics ・地域別グローバル市場分析 2015年-2020年 ・ネオ抗原がんワクチンの北米市場（アメリカ、カナダ、メキシコ） ・ネオ抗原がんワクチンのヨーロッパ市場（ドイツ、イギリス、フランス、ロシア、イタリア） ・ネオ抗原がんワクチンのアジア市場（中国、日本、韓国、インド、東南アジア、オーストラリア） ・ネオ抗原がんワクチンの南米市場（ブラジル、アルゼンチン） ・ネオ抗原がんワクチンの中東・アフリカ市場（サウジアラビア、トルコ、エジプト、南アフリカ） ・種類別分析：個別化ワクチン、市販ネオワクチン ・用途別分析：病院、クリニック、その他 ・地域別市場規模予測 2021年-2025年 ・調査の結果・結論

Market Overview
The global Neoantigen Cancer Vaccine market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of xx% in the forecast period of 2020 to 2025 and will expected to reach USD xx million by 2025, from USD xx million in 2019.

The Neoantigen Cancer Vaccine market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.

Market segmentation
Neoantigen Cancer Vaccine market is split by Type and by Application. For the period 2015-2025, the growth among segments provide accurate calculations and forecasts for sales by Type and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.

By Type, Neoantigen Cancer Vaccine market has been segmented into:
Personalized Vaccine
Off-the-shelf Neovaccines

By Application, Neoantigen Cancer Vaccine has been segmented into:
Hospital
Clinic
Others

Regions and Countries Level Analysis
Regional analysis is another highly comprehensive part of the research and analysis study of the global Neoantigen Cancer Vaccine market presented in the report. This section sheds light on the sales growth of different regional and country-level Neoantigen Cancer Vaccine markets. For the historical and forecast period 2015 to 2025, it provides detailed and accurate country-wise volume analysis and region-wise market size analysis of the global Neoantigen Cancer Vaccine market.

The report offers in-depth assessment of the growth and other aspects of the Neoantigen Cancer Vaccine market in important countries (regions), including:
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia and Australia)
South America (Brazil, Argentina, Colombia)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)

Competitive Landscape and Neoantigen Cancer Vaccine Market Share Analysis
Neoantigen Cancer Vaccine competitive landscape provides details by vendors, including company overview, company total revenue (financials), market potential, global presence, Neoantigen Cancer Vaccine sales and revenue generated, market share, price, production sites and facilities, SWOT analysis, product launch. For the period 2015-2020, this study provides the Neoantigen Cancer Vaccine sales, revenue and market share for each player covered in this report.

The major players covered in Neoantigen Cancer Vaccine are:
Roche
Neon Therapeutics
Advaxis
Medimmune
Gritstone Oncology
Merck
OSE Immunotherapeutics
Genocea
Agenus
Nouscom
Medigene
Geneos Therapeutics
Vaccibody
Brightpath Biotherapeutics

レポート目次

---

Table of Contents

1 Neoantigen Cancer Vaccine Market Overview
1.1 Product Overview and Scope of Neoantigen Cancer Vaccine
1.2 Classification of Neoantigen Cancer Vaccine by Type
1.2.1 Global Neoantigen Cancer Vaccine Revenue by Type: 2015 VS 2019 VS 2025
1.2.2 Global Neoantigen Cancer Vaccine Revenue Market Share by Type in 2019
1.2.3 Personalized Vaccine
1.2.4 Off-the-shelf Neovaccines
1.3 Global Neoantigen Cancer Vaccine Market by Application
1.3.1 Overview: Global Neoantigen Cancer Vaccine Revenue by Application: 2015 VS 2019 VS 2025
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Others
1.4 Global Neoantigen Cancer Vaccine Market by Regions
1.4.1 Global Neoantigen Cancer Vaccine Market Size by Regions: 2015 VS 2019 VS 2025
1.4.2 Global Market Size of Neoantigen Cancer Vaccine (2015-2025)
1.4.3 North America (USA, Canada and Mexico) Neoantigen Cancer Vaccine Status and Prospect (2015-2025)
1.4.4 Europe (Germany, France, UK, Russia and Italy) Neoantigen Cancer Vaccine Status and Prospect (2015-2025)
1.4.5 Asia-Pacific (China, Japan, Korea, India and Southeast Asia) Neoantigen Cancer Vaccine Status and Prospect (2015-2025)
1.4.6 South America (Brazil, Argentina, Colombia) Neoantigen Cancer Vaccine Status and Prospect (2015-2025)
1.4.7 Middle East & Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa) Neoantigen Cancer Vaccine Status and Prospect (2015-2025)
2 Company Profiles
2.1 Roche
2.1.1 Roche Details
2.1.2 Roche Major Business and Total Revenue (Financial Highlights) Analysis
2.1.3 Roche SWOT Analysis
2.1.4 Roche Product and Services
2.1.5 Roche Neoantigen Cancer Vaccine Revenue, Gross Margin and Market Share (2018-2019)
2.2 Neon Therapeutics
2.2.1 Neon Therapeutics Details
2.2.2 Neon Therapeutics Major Business and Total Revenue (Financial Highlights) Analysis
2.2.3 Neon Therapeutics SWOT Analysis
2.2.4 Neon Therapeutics Product and Services
2.2.5 Neon Therapeutics Neoantigen Cancer Vaccine Revenue, Gross Margin and Market Share (2018-2019)
2.3 Advaxis
2.3.1 Advaxis Details
2.3.2 Advaxis Major Business and Total Revenue (Financial Highlights) Analysis
2.3.3 Advaxis SWOT Analysis
2.3.4 Advaxis Product and Services
2.3.5 Advaxis Neoantigen Cancer Vaccine Revenue, Gross Margin and Market Share (2018-2019)
2.4 Medimmune
2.4.1 Medimmune Details
2.4.2 Medimmune Major Business and Total Revenue (Financial Highlights) Analysis
2.4.3 Medimmune SWOT Analysis
2.4.4 Medimmune Product and Services
2.4.5 Medimmune Neoantigen Cancer Vaccine Revenue, Gross Margin and Market Share (2018-2019)
2.5 Gritstone Oncology
2.5.1 Gritstone Oncology Details
2.5.2 Gritstone Oncology Major Business and Total Revenue (Financial Highlights) Analysis
2.5.3 Gritstone Oncology SWOT Analysis
2.5.4 Gritstone Oncology Product and Services
2.5.5 Gritstone Oncology Neoantigen Cancer Vaccine Revenue, Gross Margin and Market Share (2018-2019)
2.6 Merck
2.6.1 Merck Details
2.6.2 Merck Major Business and Total Revenue (Financial Highlights) Analysis
2.6.3 Merck SWOT Analysis
2.6.4 Merck Product and Services
2.6.5 Merck Neoantigen Cancer Vaccine Revenue, Gross Margin and Market Share (2018-2019)
2.7 OSE Immunotherapeutics
2.7.1 OSE Immunotherapeutics Details
2.7.2 OSE Immunotherapeutics Major Business and Total Revenue (Financial Highlights) Analysis
2.7.3 OSE Immunotherapeutics SWOT Analysis
2.7.4 OSE Immunotherapeutics Product and Services
2.7.5 OSE Immunotherapeutics Neoantigen Cancer Vaccine Revenue, Gross Margin and Market Share (2018-2019)
2.8 Genocea
2.8.1 Genocea Details
2.8.2 Genocea Major Business and Total Revenue (Financial Highlights) Analysis
2.8.3 Genocea SWOT Analysis
2.8.4 Genocea Product and Services
2.8.5 Genocea Neoantigen Cancer Vaccine Revenue, Gross Margin and Market Share (2018-2019)
2.9 Agenus
2.9.1 Agenus Details
2.9.2 Agenus Major Business and Total Revenue (Financial Highlights) Analysis
2.9.3 Agenus SWOT Analysis
2.9.4 Agenus Product and Services
2.9.5 Agenus Neoantigen Cancer Vaccine Revenue, Gross Margin and Market Share (2018-2019)
2.10 Nouscom
2.10.1 Nouscom Details
2.10.2 Nouscom Major Business and Total Revenue (Financial Highlights) Analysis
2.10.3 Nouscom SWOT Analysis
2.10.4 Nouscom Product and Services
2.10.5 Nouscom Neoantigen Cancer Vaccine Revenue, Gross Margin and Market Share (2018-2019)
2.11 Medigene
2.11.1 Medigene Details
2.11.2 Medigene Major Business and Total Revenue (Financial Highlights) Analysis
2.11.3 Medigene SWOT Analysis
2.11.4 Medigene Product and Services
2.11.5 Medigene Neoantigen Cancer Vaccine Revenue, Gross Margin and Market Share (2018-2019)
2.12 Geneos Therapeutics
2.12.1 Geneos Therapeutics Details
2.12.2 Geneos Therapeutics Major Business and Total Revenue (Financial Highlights) Analysis
2.12.3 Geneos Therapeutics SWOT Analysis
2.12.4 Geneos Therapeutics Product and Services
2.12.5 Geneos Therapeutics Neoantigen Cancer Vaccine Revenue, Gross Margin and Market Share (2018-2019)
2.13 Vaccibody
2.13.1 Vaccibody Details
2.13.2 Vaccibody Major Business and Total Revenue (Financial Highlights) Analysis
2.13.3 Vaccibody SWOT Analysis
2.13.4 Vaccibody Product and Services
2.13.5 Vaccibody Neoantigen Cancer Vaccine Revenue, Gross Margin and Market Share (2018-2019)
2.14 Brightpath Biotherapeutics
2.14.1 Brightpath Biotherapeutics Details
2.14.2 Brightpath Biotherapeutics Major Business and Total Revenue (Financial Highlights) Analysis
2.14.3 Brightpath Biotherapeutics SWOT Analysis
2.14.4 Brightpath Biotherapeutics Product and Services
2.14.5 Brightpath Biotherapeutics Neoantigen Cancer Vaccine Revenue, Gross Margin and Market Share (2018-2019)
3 Market Competition, by Players
3.1 Global Neoantigen Cancer Vaccine Revenue and Share by Players (2015-2020)
3.2 Market Concentration Rate
3.2.1 Top 5 Neoantigen Cancer Vaccine Players Market Share
3.2.2 Top 10 Neoantigen Cancer Vaccine Players Market Share
3.3 Market Competition Trend
4 Market Size by Regions
4.1 Global Neoantigen Cancer Vaccine Revenue and Market Share by Regions
4.2 North America Neoantigen Cancer Vaccine Revenue and Growth Rate (2015-2020)
4.3 Europe Neoantigen Cancer Vaccine Revenue and Growth Rate (2015-2020)
4.4 Asia-Pacific Neoantigen Cancer Vaccine Revenue and Growth Rate (2015-2020)
4.5 South America Neoantigen Cancer Vaccine Revenue and Growth Rate (2015-2020)
4.6 Middle East & Africa Neoantigen Cancer Vaccine Revenue and Growth Rate (2015-2020)
5 North America Neoantigen Cancer Vaccine Revenue by Countries
5.1 North America Neoantigen Cancer Vaccine Revenue by Countries (2015-2020)
5.2 USA Neoantigen Cancer Vaccine Revenue and Growth Rate (2015-2020)
5.3 Canada Neoantigen Cancer Vaccine Revenue and Growth Rate (2015-2020)
5.4 Mexico Neoantigen Cancer Vaccine Revenue and Growth Rate (2015-2020)
6 Europe Neoantigen Cancer Vaccine Revenue by Countries
6.1 Europe Neoantigen Cancer Vaccine Revenue by Countries (2015-2020)
6.2 Germany Neoantigen Cancer Vaccine Revenue and Growth Rate (2015-2020)
6.3 UK Neoantigen Cancer Vaccine Revenue and Growth Rate (2015-2020)
6.4 France Neoantigen Cancer Vaccine Revenue and Growth Rate (2015-2020)
6.5 Russia Neoantigen Cancer Vaccine Revenue and Growth Rate (2015-2020)
6.6 Italy Neoantigen Cancer Vaccine Revenue and Growth Rate (2015-2020)
7 Asia-Pacific Neoantigen Cancer Vaccine Revenue by Countries
7.1 Asia-Pacific Neoantigen Cancer Vaccine Revenue by Countries (2015-2020)
7.2 China Neoantigen Cancer Vaccine Revenue and Growth Rate (2015-2020)
7.3 Japan Neoantigen Cancer Vaccine Revenue and Growth Rate (2015-2020)
7.4 Korea Neoantigen Cancer Vaccine Revenue and Growth Rate (2015-2020)
7.5 India Neoantigen Cancer Vaccine Revenue and Growth Rate (2015-2020)
7.6 Southeast Asia Neoantigen Cancer Vaccine Revenue and Growth Rate (2015-2020)
8 South America Neoantigen Cancer Vaccine Revenue by Countries
8.1 South America Neoantigen Cancer Vaccine Revenue by Countries (2015-2020)
8.2 Brazil Neoantigen Cancer Vaccine Revenue and Growth Rate (2015-2020)
8.3 Argentina Neoantigen Cancer Vaccine Revenue and Growth Rate (2015-2020)
9 Middle East & Africa Revenue Neoantigen Cancer Vaccine by Countries
9.1 Middle East & Africa Neoantigen Cancer Vaccine Revenue by Countries (2015-2020)
9.2 Saudi Arabia Neoantigen Cancer Vaccine Revenue and Growth Rate (2015-2020)
9.3 UAE Neoantigen Cancer Vaccine Revenue and Growth Rate (2015-2020)
9.4 Egypt Neoantigen Cancer Vaccine Revenue and Growth Rate (2015-2020)
9.5 South Africa Neoantigen Cancer Vaccine Revenue and Growth Rate (2015-2020)
10 Market Size Segment by Type
10.1 Global Neoantigen Cancer Vaccine Revenue and Market Share by Type (2015-2020)
10.2 Global Neoantigen Cancer Vaccine Market Forecast by Type (2019-2024)
10.3 Personalized Vaccine Revenue Growth Rate (2015-2025)
10.4 Off-the-shelf Neovaccines Revenue Growth Rate (2015-2025)
11 Global Neoantigen Cancer Vaccine Market Segment by Application
11.1 Global Neoantigen Cancer Vaccine Revenue Market Share by Application (2015-2020)
11.2 Neoantigen Cancer Vaccine Market Forecast by Application (2019-2024)
11.3 Hospital Revenue Growth (2015-2020)
11.4 Clinic Revenue Growth (2015-2020)
11.5 Others Revenue Growth (2015-2020)
12 Global Neoantigen Cancer Vaccine Market Size Forecast (2021-2025)
12.1 Global Neoantigen Cancer Vaccine Market Size Forecast (2021-2025)
12.2 Global Neoantigen Cancer Vaccine Market Forecast by Regions (2021-2025)
12.3 North America Neoantigen Cancer Vaccine Revenue Market Forecast (2021-2025)
12.4 Europe Neoantigen Cancer Vaccine Revenue Market Forecast (2021-2025)
12.5 Asia-Pacific Neoantigen Cancer Vaccine Revenue Market Forecast (2021-2025)
12.6 South America Neoantigen Cancer Vaccine Revenue Market Forecast (2021-2025)
12.7 Middle East & Africa Neoantigen Cancer Vaccine Revenue Market Forecast (2021-2025)
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Data Source
14.3 Disclaimer
14.4 About US

List of Tables

Table 1. Global Neoantigen Cancer Vaccine Revenue (USD Million) by Type: 2015 VS 2019 VS 2025
Table 2. Breakdown of Neoantigen Cancer Vaccine by Company Type (Tier 1, Tier 2 and Tier 3)
Table 3. Global Neoantigen Cancer Vaccine Revenue (USD Million) by Application: 2015 VS 2019 VS 2025
Table 4. Global Market Neoantigen Cancer Vaccine Revenue (Million USD) Comparison by Regions 2015-2025
Table 5. Roche Corporate Information, Location and Competitors
Table 6. Roche Neoantigen Cancer Vaccine Major Business
Table 7. Roche Neoantigen Cancer Vaccine Total Revenue (USD Million) (2017-2018)
Table 8. Roche SWOT Analysis
Table 9. Roche Neoantigen Cancer Vaccine Product and Solutions
Table 10. Roche Neoantigen Cancer Vaccine Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 11. Neon Therapeutics Corporate Information, Location and Competitors
Table 12. Neon Therapeutics Neoantigen Cancer Vaccine Major Business
Table 13. Neon Therapeutics Neoantigen Cancer Vaccine Total Revenue (USD Million) (2018-2019)
Table 14. Neon Therapeutics SWOT Analysis
Table 15. Neon Therapeutics Neoantigen Cancer Vaccine Product and Solutions
Table 16. Neon Therapeutics Neoantigen Cancer Vaccine Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 17. Advaxis Corporate Information, Location and Competitors
Table 18. Advaxis Neoantigen Cancer Vaccine Major Business
Table 19. Advaxis Neoantigen Cancer Vaccine Total Revenue (USD Million) (2017-2018)
Table 20. Advaxis SWOT Analysis
Table 21. Advaxis Neoantigen Cancer Vaccine Product and Solutions
Table 22. Advaxis Neoantigen Cancer Vaccine Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 23. Medimmune Corporate Information, Location and Competitors
Table 24. Medimmune Neoantigen Cancer Vaccine Major Business
Table 25. Medimmune Neoantigen Cancer Vaccine Total Revenue (USD Million) (2017-2018)
Table 26. Medimmune SWOT Analysis
Table 27. Medimmune Neoantigen Cancer Vaccine Product and Solutions
Table 28. Medimmune Neoantigen Cancer Vaccine Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 29. Gritstone Oncology Corporate Information, Location and Competitors
Table 30. Gritstone Oncology Neoantigen Cancer Vaccine Major Business
Table 31. Gritstone Oncology Neoantigen Cancer Vaccine Total Revenue (USD Million) (2017-2018)
Table 32. Gritstone Oncology SWOT Analysis
Table 33. Gritstone Oncology Neoantigen Cancer Vaccine Product and Solutions
Table 34. Gritstone Oncology Neoantigen Cancer Vaccine Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 35. Merck Corporate Information, Location and Competitors
Table 36. Merck Neoantigen Cancer Vaccine Major Business
Table 37. Merck Neoantigen Cancer Vaccine Total Revenue (USD Million) (2017-2018)
Table 38. Merck SWOT Analysis
Table 39. Merck Neoantigen Cancer Vaccine Product and Solutions
Table 40. Merck Neoantigen Cancer Vaccine Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 41. OSE Immunotherapeutics Corporate Information, Location and Competitors
Table 42. OSE Immunotherapeutics Neoantigen Cancer Vaccine Major Business
Table 43. OSE Immunotherapeutics Neoantigen Cancer Vaccine Total Revenue (USD Million) (2017-2018)
Table 44. OSE Immunotherapeutics SWOT Analysis
Table 45. OSE Immunotherapeutics Neoantigen Cancer Vaccine Product and Solutions
Table 46. OSE Immunotherapeutics Neoantigen Cancer Vaccine Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 47. Genocea Corporate Information, Location and Competitors
Table 48. Genocea Neoantigen Cancer Vaccine Major Business
Table 49. Genocea Neoantigen Cancer Vaccine Total Revenue (USD Million) (2017-2018)
Table 50. Genocea SWOT Analysis
Table 51. Genocea Neoantigen Cancer Vaccine Product and Solutions
Table 52. Genocea Neoantigen Cancer Vaccine Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 53. Agenus Corporate Information, Location and Competitors
Table 54. Agenus Neoantigen Cancer Vaccine Major Business
Table 55. Agenus Neoantigen Cancer Vaccine Total Revenue (USD Million) (2017-2018)
Table 56. Agenus SWOT Analysis
Table 57. Agenus Neoantigen Cancer Vaccine Product and Solutions
Table 58. Agenus Neoantigen Cancer Vaccine Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 59. Nouscom Corporate Information, Location and Competitors
Table 60. Nouscom Neoantigen Cancer Vaccine Major Business
Table 61. Nouscom Neoantigen Cancer Vaccine Total Revenue (USD Million) (2017-2018)
Table 62. Nouscom SWOT Analysis
Table 63. Nouscom Neoantigen Cancer Vaccine Product and Solutions
Table 64. Nouscom Neoantigen Cancer Vaccine Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 65. Medigene Corporate Information, Location and Competitors
Table 66. Medigene Neoantigen Cancer Vaccine Major Business
Table 67. Medigene Neoantigen Cancer Vaccine Total Revenue (USD Million) (2017-2018)
Table 68. Medigene SWOT Analysis
Table 69. Medigene Neoantigen Cancer Vaccine Product and Solutions
Table 70. Medigene Neoantigen Cancer Vaccine Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 71. Geneos Therapeutics Corporate Information, Location and Competitors
Table 72. Geneos Therapeutics Neoantigen Cancer Vaccine Major Business
Table 73. Geneos Therapeutics Neoantigen Cancer Vaccine Total Revenue (USD Million) (2017-2018)
Table 74. Geneos Therapeutics SWOT Analysis
Table 75. Geneos Therapeutics Neoantigen Cancer Vaccine Product and Solutions
Table 76. Geneos Therapeutics Neoantigen Cancer Vaccine Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 77. Vaccibody Corporate Information, Location and Competitors
Table 78. Vaccibody Neoantigen Cancer Vaccine Major Business
Table 79. Vaccibody Neoantigen Cancer Vaccine Total Revenue (USD Million) (2017-2018)
Table 80. Vaccibody SWOT Analysis
Table 81. Vaccibody Neoantigen Cancer Vaccine Product and Solutions
Table 82. Vaccibody Neoantigen Cancer Vaccine Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 83. Brightpath Biotherapeutics Corporate Information, Location and Competitors
Table 84. Brightpath Biotherapeutics Neoantigen Cancer Vaccine Major Business
Table 85. Brightpath Biotherapeutics Neoantigen Cancer Vaccine Total Revenue (USD Million) (2017-2018)
Table 86. Brightpath Biotherapeutics SWOT Analysis
Table 87. Brightpath Biotherapeutics Neoantigen Cancer Vaccine Product and Solutions
Table 88. Brightpath Biotherapeutics Neoantigen Cancer Vaccine Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 89. Global Neoantigen Cancer Vaccine Revenue (Million USD) by Players (2015-2020)
Table 90. Global Neoantigen Cancer Vaccine Revenue Share by Players (2015-2020)
Table 91. Global Neoantigen Cancer Vaccine Revenue (Million USD) by Regions (2015-2020)
Table 92. Global Neoantigen Cancer Vaccine Revenue Market Share by Regions (2015-2020)
Table 93. North America Neoantigen Cancer Vaccine Revenue by Countries (2015-2020)
Table 94. North America Neoantigen Cancer Vaccine Revenue Market Share by Countries (2015-2020)
Table 95. Europe Neoantigen Cancer Vaccine Revenue (Million USD) by Countries (2015-2020)
Table 96. Asia-Pacific Neoantigen Cancer Vaccine Revenue (Million USD) by Countries (2015-2020)
Table 97. South America Neoantigen Cancer Vaccine Revenue by Countries (2015-2020)
Table 98. South America Neoantigen Cancer Vaccine Revenue Market Share by Countries (2015-2020)
Table 99. Middle East and Africa Neoantigen Cancer Vaccine Revenue (Million USD) by Countries (2015-2020)
Table 100. Middle East and Africa Neoantigen Cancer Vaccine Revenue Market Share by Countries (2015-2020)
Table 101. Global Neoantigen Cancer Vaccine Revenue (Million USD) by Type (2015-2020)
Table 102. Global Neoantigen Cancer Vaccine Revenue Share by Type (2015-2020)
Table 103. Global Neoantigen Cancer Vaccine Revenue Forecast by Type (2021-2025)
Table 104. Global Neoantigen Cancer Vaccine Revenue by Application (2015-2020)
Table 105. Global Neoantigen Cancer Vaccine Revenue Share by Application (2015-2020)
Table 106. Global Neoantigen Cancer Vaccine Revenue Forecast by Application (2021-2025)
Table 107. Global Neoantigen Cancer Vaccine Revenue (Million USD) Forecast by Regions (2021-2025)
List of Figures
Figure 1. Neoantigen Cancer Vaccine Picture
Figure 2. Global Neoantigen Cancer Vaccine Revenue Market Share by Type in 2019
Figure 3. Personalized Vaccine Picture
Figure 4. Off-the-shelf Neovaccines Picture
Figure 5. Neoantigen Cancer Vaccine Revenue Market Share by Application in 2019
Figure 6. Hospital Picture
Figure 7. Clinic Picture
Figure 8. Others Picture
Figure 9. Global Neoantigen Cancer Vaccine Revenue (USD Million) and Growth Rate (2015-2025)
Figure 10. North America Neoantigen Cancer Vaccine Revenue (Million USD) and Growth Rate (2015-2025)
Figure 11. Europe Neoantigen Cancer Vaccine Revenue (Million USD) and Growth Rate (2015-2025)
Figure 12. Asia-Pacific Neoantigen Cancer Vaccine Revenue (Million USD) and Growth Rate (2015-2025)
Figure 13. South America Neoantigen Cancer Vaccine Revenue (Million USD) and Growth Rate (2015-2025)
Figure 14. Middle East and Africa Neoantigen Cancer Vaccine Revenue (Million USD) and Growth Rate (2015-2025)
Figure 15. Global Neoantigen Cancer Vaccine Revenue (Million USD) and Growth Rate (2015-2025)
Figure 16. Global Neoantigen Cancer Vaccine Revenue Share by Players in 2019
Figure 17. Global Top 5 Players Neoantigen Cancer Vaccine Revenue Market Share in 2019
Figure 18. Global Top 10 Players Neoantigen Cancer Vaccine Revenue Market Share in 2019
Figure 19. Key Players Market Share Trend
Figure 20. Global Neoantigen Cancer Vaccine Revenue (Million USD) and Growth Rate (%) (2015-2020)
Figure 21. Global Neoantigen Cancer Vaccine Revenue Market Share by Regions (2015-2020)
Figure 22. Global Neoantigen Cancer Vaccine Revenue Market Share by Regions in 2018
Figure 23. North America Neoantigen Cancer Vaccine Revenue and Growth Rate (2015-2020)
Figure 24. Europe Neoantigen Cancer Vaccine Revenue and Growth Rate (2015-2020)
Figure 25. Asia-Pacific Neoantigen Cancer Vaccine Revenue and Growth Rate (2015-2020)
Figure 26. South America Neoantigen Cancer Vaccine Revenue and Growth Rate (2015-2020)
Figure 27. Middle East and Africa Neoantigen Cancer Vaccine Revenue and Growth Rate (2015-2020)
Figure 28. North America Neoantigen Cancer Vaccine Revenue Market Share by Countries (2015-2020)
Figure 29. North America Neoantigen Cancer Vaccine Revenue Market Share by Countries in 2019
Figure 30. USA Neoantigen Cancer Vaccine Revenue and Growth Rate (2015-2020)
Figure 31. Canada Neoantigen Cancer Vaccine Revenue and Growth Rate (2015-2020)
Figure 32. Mexico Neoantigen Cancer Vaccine Revenue and Growth Rate (2015-2020)
Figure 33. Europe Neoantigen Cancer Vaccine Revenue Market Share by Countries (2015-2020)
Figure 34. Europe Neoantigen Cancer Vaccine Revenue Market Share by Countries in 2019
Figure 35. Germany Neoantigen Cancer Vaccine Revenue and Growth Rate (2015-2020)
Figure 36. UK Neoantigen Cancer Vaccine Revenue and Growth Rate (2015-2020)
Figure 37. France Neoantigen Cancer Vaccine Revenue and Growth Rate (2015-2020)
Figure 38. Russia Neoantigen Cancer Vaccine Revenue and Growth Rate (2015-2020)
Figure 39. Italy Neoantigen Cancer Vaccine Revenue and Growth Rate (2015-2020)
Figure 40. Asia-Pacific Neoantigen Cancer Vaccine Revenue Market Share by Countries (2015-2020)
Figure 41. Asia-Pacific Neoantigen Cancer Vaccine Revenue Market Share by Countries in 2019
Figure 42. China Neoantigen Cancer Vaccine Revenue and Growth Rate (2015-2020)
Figure 43. Japan Neoantigen Cancer Vaccine Revenue and Growth Rate (2015-2020)
Figure 44. Korea Neoantigen Cancer Vaccine Revenue and Growth Rate (2015-2020)
Figure 45. India Neoantigen Cancer Vaccine Revenue and Growth Rate (2015-2020)
Figure 46. Southeast Asia Neoantigen Cancer Vaccine Revenue and Growth Rate (2015-2020)
Figure 47. South America Neoantigen Cancer Vaccine Revenue Market Share by Countries (2015-2020)
Figure 48. South America Neoantigen Cancer Vaccine Revenue Market Share by Countries in 2019
Figure 49. Brazil Neoantigen Cancer Vaccine Revenue and Growth Rate (2015-2020)
Figure 50. Argentina Neoantigen Cancer Vaccine Revenue and Growth Rate (2015-2020)
Figure 51. Middle East and Africa Neoantigen Cancer Vaccine Revenue Market Share by Countries (2015-2020)
Figure 52. Middle East and Africa Neoantigen Cancer Vaccine Revenue Market Share by Countries in 2019
Figure 53. Saudi Arabia Neoantigen Cancer Vaccine Revenue and Growth Rate (2015-2020)
Figure 54. UAE Neoantigen Cancer Vaccine Revenue and Growth Rate (2015-2020)
Figure 55. Egypt Neoantigen Cancer Vaccine Revenue and Growth Rate (2015-2020)
Figure 56. South Africa Neoantigen Cancer Vaccine Revenue and Growth Rate (2015-2020)
Figure 57. Global Neoantigen Cancer Vaccine Revenue Share by Type (2015-2020)
Figure 58. Global Neoantigen Cancer Vaccine Revenue Share by Type in 2019
Figure 59. Global Neoantigen Cancer Vaccine Market Share Forecast by Type (2021-2025)
Figure 60. Global Personalized Vaccine Revenue Growth Rate (2015-2020)
Figure 61. Global Off-the-shelf Neovaccines Revenue Growth Rate (2015-2020)
Figure 62. Global Neoantigen Cancer Vaccine Revenue Share by Application (2015-2020)
Figure 63. Global Neoantigen Cancer Vaccine Revenue Share by Application in 2019
Figure 64. Global Neoantigen Cancer Vaccine Market Share Forecast by Application (2021-2025)
Figure 65. Global Hospital Revenue Growth Rate (2015-2020)
Figure 66. Global Clinic Revenue Growth Rate (2015-2020)
Figure 67. Global Others Revenue Growth Rate (2015-2020)
Figure 68. Global Neoantigen Cancer Vaccine Revenue (Million USD) and Growth Rate Forecast (2021-2025)
Figure 69. Global Neoantigen Cancer Vaccine Revenue (Million USD) Forecast by Regions (2021-2025)
Figure 70. Global Neoantigen Cancer Vaccine Revenue Market Share Forecast by Regions (2021-2025)
Figure 71. North America Neoantigen Cancer Vaccine Revenue Market Forecast (2021-2025)
Figure 72. Europe Neoantigen Cancer Vaccine Revenue Market Forecast (2021-2025)
Figure 73. Asia-Pacific Neoantigen Cancer Vaccine Revenue Market Forecast (2021-2025)
Figure 74. South America Neoantigen Cancer Vaccine Revenue Market Forecast (2021-2025)
Figure 75. Middle East and Africa Neoantigen Cancer Vaccine Revenue Market Forecast (2021-2025)
Figure 76. Sales Channel: Direct Channel vs Indirect Channel

---